Novartis Ag

Andreas Kordikowski

Siyi Jiang

Zachary Kevin Sweeney

Jiping Fu

Christopher Ronald Sarko

Thomas Martin Kirrane, Jr

Gebhard Thoma

Nicole Blaquiere

Benjamin R Taft

Yugang Liu

Fumiaki Yokokawa

Wolfgang Miltz

Rita Ramos

Till Roehn

Tingying Zhu

Christian Markert

Yi Zhao

Nicole Bieri

Philipp Lustenberger

Bin Li

Vijay Sethuraman

Hongyong Kim

Richard Yichong Huang

Sisi Zhang

Yanxiang Wu

Jing Zhang

Bo Yu

Irene Xia

Yudong Cao

Rainer Martin Lüönd

Tian Xie

Grace Lamprecht Waldron

Anne-Catherine Mata

Carsten Spanka

Rainer Martin LÜÖND

This application relates to various crystalline forms of (S)—N-(4-((5-(1,6-dimethyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-1-yl)methyl)bicyclo[2.2.2]octan-1-yl)morpholine-3-carboxamide in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water ('hydrates'). These materials are useful in the treatment of various autoimmune diseases, including systemic lupus erythematosus, cutaneous lupus, discoid lupus, mixed connective tissue disease, primary biliary cirrhosis, immune thrombocytopenia purpura, hidradenitis suppurativa, dermatomyositis, polymyositis, Sjögren's syndrome, arthritis, rheumatoid arthritis and psoriasis.

Crystalline forms of a TLR7/TLR8 inhibitor

This application relates to various crystalline forms of (S)-3-amino-4-(5-(4-((5-chloro-3-fluoropyridin-2-yl)oxy)phenyl)-2H-tetrazol-2-yl)butanoic acid in its free form, as well as compositions, method of making and methods of using the same. In some embodiments the crystalline forms also contain water ('hydrates'). These materials are useful in the treatment of diseases and disorders which are typically ameliorated by the inhibition of LTA4H. Such diseases and disorders may include inflammatory and autoimmune disorders and pulmonary and respiratory tract inflammation.

Crystalline forms of a LTA4H inhibitor

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Heteroaryl aminopropanol derivatives

The application relates to N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide (Compound I) fumaric acid co-crystals and X-ray amorphous complexes of Compound (I) and fumaric acid. The application also provides methods of making the same; pharmaceutical compositions comprising them; and their use in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a kinetoplastid parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

Solid forms of N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; 

Compounds and compositions for the treatment of parasitic diseases

This invention pertains to a crystalline compound of Formula (A) as described herein and compositions containing this crystalline compound, as well as methods of using the compound or pharmaceutical compositions comprising it to treat bacterial infections. The compound and compositions are especially useful to treat Gram negative bacterial infections, including multi-drug resistant strains. 

Crystalline isoxazole hydroxamic acid compounds

Growing community of inventors

Basel, Switzerland

Andreas Kordikowski